Catheter Precision, Inc. (VTAK)
CIK 1716621 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 2.7M shares as of May 8, 2026 (10-Q). Share count fell from 54.5M to 2.2M between Aug 10, 2022 and Nov 9, 2022, a pattern consistent with a reverse split (roughly 1-for-25); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| October2024 Series K Warrants | 562,945 | $13.3 | — | — |
| Series M Warrants | 340,000 | $1.56 | 5.5y | FV $509,000 |
| September2024 Series J Warrants | 188,363 | $19 | — | — |
| Series H Warrants | 26,316 | $19 | — | — |
| Series I Warrants | 26,316 | $19 | — | — |
| Series J Warrants | 26,316 | $19 | — | — |
| May2020 Placement Agent Warrants | 16,888 | $20.62 | — | — |
| August2020 Placement Agent Warrants | 13,534 | $10.31 | — | — |
| Placement Agent Warrants | 13,534 | $10.3075 | 5y | — |
| Prefunded Warrants | 12,368 | $0.0019 | — | — |
| September2024 Representative Warrants | 11,302 | $29.45 | — | — |
| February2022 Series B Warrants | 2,061 | $2660 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed May 18, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 1.1M underlying shares, as reported Mar 31, 2026 (10-Q).
Reported exercise price: $0.0001 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 3.8M = 2.7M O/S + 1.1M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Other Assumed Notes | $1.3M | — | $1.8 | — | ~722,222 sh |
| Secured Debt | not tagged | $1.3M | not tagged | — | — |
| Boot Capital Second Convertible Note Payable | $204,000 | — | not tagged | — | — |
| Boot Capital First Convertible Note Payable | $102,000 | — | not tagged | — | — |
If every note above converted at its tagged price: ~722,222 new shares on 2.7M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed May 18, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 2.7M | May 8, 2026 |
| + October2024 Series K Warrants (if exercised) | 562,945 | Mar 31, 2026 |
| + Series M Warrants (if exercised) | 340,000 | Mar 31, 2026 |
| + September2024 Series J Warrants (if exercised) | 188,363 | Mar 31, 2026 |
| + Series H Warrants (if exercised) | 26,316 | Sep 3, 2024 |
| + Series I Warrants (if exercised) | 26,316 | Sep 3, 2024 |
| + Series J Warrants (if exercised) | 26,316 | Sep 3, 2024 |
| + May2020 Placement Agent Warrants (if exercised) | 16,888 | Mar 31, 2026 |
| + August2020 Placement Agent Warrants (if exercised) | 13,534 | Mar 31, 2026 |
| + Placement Agent Warrants (if exercised) | 13,534 | May 12, 2025 |
| + Prefunded Warrants (if exercised) | 12,368 | Sep 3, 2024 |
| + September2024 Representative Warrants (if exercised) | 11,302 | Mar 31, 2026 |
| + February2022 Series B Warrants (if exercised) | 2,061 | Mar 31, 2026 |
| + Other Assumed Notes (if fully converted) | 722,222 | Mar 9, 2026 |
| Fully diluted estimate | 4.7M | +72.9% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $64.7Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 6 executed · 2 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full VTAK workspace